NFGH
LBRX

Nan Fung Group Holdings’s LB Pharmaceuticals LBRX Stock Holding History

Nan Fung Group Holdings’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Hold
630,657
– – 15.57% 2
2026
Q1 		$15.6M Buy
630,657
+330,657
+110% +$7.63M 12.82% 3
2025
Q4 		$6.68M Hold
300,000
– – 5.98% 5
2025
Q3 		$4.74M Buy
+300,000
New +$4.76M 7.95% 6

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Nan Fung Group Holdings's LBRX Position: Q2 2026 in Review

Nan Fung Group Holdings held its LB Pharmaceuticals (LBRX) position steady in Q2 2026 at 630,657 shares worth $20.5M. The position accounts for 15.57% of the portfolio, ranked #2.

Nan Fung Group Holdings first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Nan Fung Group Holdings held 630,657 shares of LB Pharmaceuticals worth $20.5M as of Q2 2026.
  • Nan Fung Group Holdings left its LB Pharmaceuticals share count unchanged in Q2 2026.
  • LB Pharmaceuticals made up 15.57% of Nan Fung Group Holdings's portfolio in Q2 2026, its #2 holding.
  • Nan Fung Group Holdings first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Nan Fung Group Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.